Compare OTEX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTEX | LQDA |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.5B |
| IPO Year | 1998 | 2020 |
| Metric | OTEX | LQDA |
|---|---|---|
| Price | $28.06 | $40.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $27.95 | ★ $54.38 |
| AVG Volume (30 Days) | 1.2M | ★ 4.8M |
| Earning Date | 11-05-2026 | 11-06-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | ★ 56.36 | 51.81 |
| EPS | ★ 2.58 | 1.26 |
| Revenue | ★ $2,815,241,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $357.27 |
| Revenue Next Year | $1.67 | $1.34 |
| P/E Ratio | ★ $10.81 | $31.31 |
| Revenue Growth | 22.88 | ★ 1031.18 |
| 52 Week Low | $19.78 | $22.05 |
| 52 Week High | $39.81 | $93.61 |
| Indicator | OTEX | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 80.34 | 44.79 |
| Support Level | $21.79 | $35.00 |
| Resistance Level | N/A | $40.60 |
| Average True Range (ATR) | 0.77 | 2.74 |
| MACD | 0.49 | 2.19 |
| Stochastic Oscillator | 99.66 | 99.91 |
Open Text Corp provides data management for enterprise AI, offering a secure data foundation and trusted context for credible AI outcomes across private, public, and sovereign cloud, managed cloud services, API, and on-premises environments. The Company also provides cybersecurity solutions to protect sensitive data, applications and systems across complex hybrid environments, including identity and access management, threat detection and response, data protection and application security. It serves private, public, and regulated sectors, including retail, financial services, government, manufacturing, healthcare, energy, and logistics, with clients. Geographically, it derives maximum revenue from the Americas.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.